Andreas Naegeli
Head, Business Development Genovis AB
Seminars
Wednesday 5th November 2025
GlyCLICK®: A Precise & Versatile Conjugation Platform for Improved ADCs
11:30 am
- Showcasing GlyCLICK® site-specific conjugation that produces homogeneous ADCs with a defined drug-to-antibody ratio while preserving antibody function
- Exploring how the platform supports controlled ADC generation and applies to a wide range of antibody formats and payloads
- Laying out case studies and preclinical examples demonstrate how GlyCLICK® is used in the development of novel ADCs
